NEW YORK (GenomeWeb News) – Clinical lab services company NeoGenomics will offer two of Response Genetics’ tests, one for colon cancer and another for lung cancer, the companies said today.
NeoGenomics will exclusively offer the ResponseDX: Colon test for colorectal cancer and the ResponseDX: Lung test for non-small-cell lung cancer through its US sales force, the companies said.
All of the tests contracted under the agreement will be performed through Response Genetics’ CLIA-certified lab. These PCR-based tests are aimed at helping doctors make treatment decisions for patients with colorectal and lung cancer.
The ResponseDX panels include analysis of the KRAS mutation, gene expression profiling of RRM1, and up to three other patent-protected genes, including ERCC1, TS, and EGFR.
The KRAS mutation is used as a predictor of whether patients will respond to the common treatment regimens for these types of cancers. Gene expression results from the panels are used to help oncologists choose between several standard chemotherapy regimens.
Response Genetics also noted that it has formed a specialized sales team to market the ResponseDX tests.
NeoGenomics Chief Scientific Officer Robert Gasparini said the joint sales strategy “will allow us to establish new accounts, differentiate our services, and increase our footprint in the expanding field of molecular cancer genetics.”
Ft. Myers, Fla.-based NeoGenomics’ testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, morphology studies, anatomic pathology, and molecular genetic testing.